{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-HZH8MXV6/a613f459-6ec4-4c82-a8d5-d084a105866f/PDF","dcterms:extent":"928 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-HZH8MXV6/79c38bf3-95e3-4227-8b88-634a81542014/TEXT","dcterms:extent":"28 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-HZH8MXV6","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2025","dc:creator":["Gobec, Martina","Smrdel, Lara"],"dc:format":[{"@xml:lang":"sl","#text":"številka:5"},{"@xml:lang":"sl","#text":"letnik:76"},{"@xml:lang":"sl","#text":"str. 313-319"}],"dc:identifier":["ISSN:2536-4316","COBISSID_HOST:266055939","URN:URN:NBN:SI:doc-HZH8MXV6"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"cancer progression"},{"@xml:lang":"sl","#text":"Farmakoterapija"},{"@xml:lang":"en","#text":"metastasis"},{"@xml:lang":"sl","#text":"Metastaze"},{"@xml:lang":"sl","#text":"napredovanje raka"},{"@xml:lang":"en","#text":"platelets"},{"@xml:lang":"sl","#text":"Rak (medicina)"},{"@xml:lang":"sl","#text":"terapevtski pristopi"},{"@xml:lang":"en","#text":"therapeutic approaches"},{"@xml:lang":"sl","#text":"trombociti"},{"@xml:lang":"sl","#text":"zasevanje"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Vloga trombocitov pri nastanku zasevkov raka| The role of platelets in cancer metastasis| mehanizmi delovanja in potencialni terapevtski pristopi| mechanisms of action and potential therapeutic approaches|"},"dc:description":[{"@xml:lang":"sl","#text":"Cancer represents a heterogeneous group of diseases characterized by uncontrolled cell proliferation and invasion. Over the past decade, research has shown that, in addition to regulating hemostasis, platelets interact with tumour cells, contributing to their survival in circulation and facilitating colonization in secondary organs. The interaction between platelets and tumour cells occurs through direct cell contacts and the release of bioactive mediators. Given the important role of platelets in cancer metastasis, therapeutic strategies targeting platelet–tumour cell interactions are being explored. Potential approaches include inhibitors of platelet activation, monoclonal antibodies against adhesion molecules, and angiogenesis inhibitors. While these strategies hold promise for improving the outcomes in cancer treatment, further research is needed for clinical implementation"},{"@xml:lang":"sl","#text":"Rak predstavlja heterogeno skupino bolezni, za katere je značilna nenadzorovana proliferacija in invazija celic. V zadnjem desetletju so raziskave pokazale, da trombociti poleg uravnavanja hemostaze, sodelujejo tudi pri interakciji s tumorskimi celicami in prispevajo k njihovemu preživetju v krvnem obtoku ter tako olajšajo kolonizacijo v sekundarnih organih. Interakcija trombocitov s tumorskimi celicami poteka preko neposrednih celičnih stikov in sproščanja bioaktivnih mediatorjev. Zaradi ključne vloge trombocitov pri zasevanju raka se proučuje terapevtske pristope, ki bi omejili interakcijo med trombociti in tumorskimi celicami. Možni pristopi vključujejo zaviralce trombocitne aktivacije, monoklonska protitelesa proti adhezijskim molekulam ter zaviralce angiogeneze. Vse te strategije sicer kažejo potencial za izboljšanje izidov pri zdravljenja raka, vendar so potrebne nadaljnje študije za potrditev morebitne implementacije v klinično prakso"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-HZH8MXV6","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-HZH8MXV6"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-HZH8MXV6/a613f459-6ec4-4c82-a8d5-d084a105866f/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-HZH8MXV6/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-HZH8MXV6"}}}}